The development of resistance to conventional treatment has led WHO to recommned the use of combination therapies containing aemisinin derivative (aemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except -
Ans. is 'b' i.e. Aesunate plus quinine The WHO recommended ACTs (aemisinin-based combination therapies) o Aemether + lumefantrine o Aesunate + sulfadoxine-pyrimethamine o Aesunate + amodiaquine o Aesunate + mefloquine o Dihydroaemisinin + piperaquine.
Aemether plus lumefantrine
Aesunate plus quinine
Aesunate plus pyrimethamine-sulfadoxine
Aesunate plus mefloquine